文献速递白血病淋巴瘤

阿扎胞苷与维奈克拉对婴儿KMT2A重排急性淋巴细胞白血病的临床前疗效揭示新治疗策略

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
PubMed 文献 · Leukemia · 2022-11-15

本研究在体外和异种移植模型中评估去甲基化药物与维奈克拉对KMT2A重排婴儿B细胞急性淋巴细胞白血病的疗效。去甲基化药物与多数传统化疗药体外呈相加作用,但与甲氨蝶呤联用部分样本呈拮抗;阿扎胞苷和地西他滨单药显著延长异种移植小鼠生存,维奈克拉与阿扎胞苷联用进一步带来显著体内生存优势。

要点

  • 去甲基化药物与多数传统化疗药体外呈相加作用,但与甲氨蝶呤在部分样本中呈拮抗。
  • 阿扎胞苷和地西他滨单药显著延长KMT2A重排婴儿ALL异种移植小鼠的生存。
  • 维奈克拉与阿扎胞苷联用较单药阿扎胞苷带来显著体内生存优势。

核心结论

  • 阿扎胞苷与维奈克拉联用显示出改善KMT2A重排婴儿ALL结局的治疗潜力。

研究设计与样本

  • 临床前研究,采用KMT2A重排婴儿ALL细胞系、患者样本及异种移植模型进行体外与体内评估。

主要发现

  • 去甲基化药物与多数传统化疗药体外呈相加作用,但部分样本中与甲氨蝶呤联用呈拮抗,ATP结合盒转运体上调为潜在机制。
  • 阿扎胞苷和地西他滨单药显著延长KMT2A重排婴儿ALL异种移植小鼠的生存。
  • 阿扎胞苷和地西他滨处理细胞系引起全基因组DNA甲基化差异和基因表达改变,热蛋白质组分析揭示了这些药物的靶蛋白结合谱。
  • 维奈克拉与去甲基化药物或传统化疗药体外呈相加作用。
  • 维奈克拉加入阿扎胞苷后带来显著体内生存优势。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. KMT2A-rearranged infant ALL cells are characterized by an abundance of promoter hypermethylation and exhibit high BCL-2 expression, highlighting potential for therapeutic targeting. Here, we show that hypomethylating agents exhibit in vitro additivity when combined with most conventional chemotherapeutic agents. However, in a subset of samples an antagonistic effect was seen between several agents. This was most evident when hypomethylating agents were combined with methotrexate, with upregulation of ATP-binding cassette transporters identified as a potential mechanism. Single agent treatment with azacitidine and decitabine significantly prolonged in vivo survival in KMT2A-rearranged infant ALL xenografts. Treatment of KMT2A-rearranged infant ALL cell lines with azacitidine and decitabine led to differential genome-wide DNA methylation, changes in gene expression and thermal proteome profiling revealed the target protein-binding landscape of these agents. The selective BCL-2 inhibitor, venetoclax, exhibited in vitro additivity in combination with hypomethylating or conventional chemotherapeutic agents. The addition of venetoclax to azacitidine resulted in a significant in vivo survival advantage indicating the therapeutic potential of this combination to improve outcome for infants with KMT2A-rearranged ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Cheung LC, Aya-Bonilla C, Cruickshank MN, et al. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. Leukemia. 2022. PMID: 36380143. doi:10.1038/s41375-022-01746-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。